Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-DEXDOCOVID
2024-511898-30-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexmedetomidine in acute respiratory distress syndrome (ARDS), coronavirus disease 2019 (COVID-19), delirium and 1 more (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Persistent neuroinflammation in frontal lobes assessed by [18F]-DPA-714 PET-MRI and [18F]-DPA-714 uptake ratio (frontal lobes to cerebellar lobes). Started Oct 2024; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)deliriumcognitive disorder (CD)
Beyond the preview
Go deeper on 2024-511898-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511898-30-00.